Previous 10 | Next 10 |
Arbutus Biopharma Corporation (ABUS) Q2 2020 Earnings Conference Call August 7, 2020 08:45 a.m. ET Company Representatives Bill Collier - President, Chief Executive Officer Mike Sofia - Chief Scientific Officer Gaston Picchio - Chief Development Officer Dave Hastings - Chief Fi...
Arbutus Biopharma ( ABUS ) Q2 results : More news on: Arbutus Biopharma Corporation, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
Arbutus Biopharma (NASDAQ: ABUS ) : Q2 GAAP EPS of -$0.25 misses by $0.01 . More news on: Arbutus Biopharma Corporation, Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
Phase 1a/1b clinical trial for AB-729, a subcutaneously delivered RNAi agent, remains on track with results from additional cohorts expected in the second half of 2020 AB-836, an oral capsid inhibitor, remains on track for completion of IND enabling studies by the end of 2020 Acti...
Written by Scott Matusow and Danny Cohen There's been a lot of hype on Arbutus (ABUS) as of late. The company recently successfully beat back a challenge to their general Intellectual Property ((IP)) that Moderna ( MRNA ) claimed was invalid - Moderna lost. However, we think th...
Analysts Appear Bullish On These Penny Stocks It has been a big year for penny stocks and analysts are taking notice. In fact, some of the most talked-about names recently – Kodak, Novavax, Workhorse Group, Nio – were all penny stocks earlier this year. Hindsight is 20/20, of c...
WARMINSTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (includin...
Dismal economic data that pressured the entire market at the end of July rolled right off the backs of some high-flying healthcare stocks. These three more than doubled, all for very different reasons. Here's what sent their share prices screaming higher. Data source: Yahoo! Finance. Continu...
There are multiple bear arguments floating around as reasons to sell Moderna (NASDAQ: MRNA) , one of the drugmakers leading the way to develop a coronavirus vaccine. Most of them don't hold much water. Image source: Getty Images. Continue reading
WARMINSTER, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (includin...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...